9 July 2021 - Late treatment study
N-acetylcysteine for the treatment of COVID-19 among hospitalized patients
et al., Journal of Infection, doi:10.1016/j.jinf.2021.07.003 (Peer Reviewed)
Prospective study of 24 hospitalized COVID-19 patients in Russia treated with NAC, and 22 matched controls, showing significantly improved SpO2/FiO2, and significantly shorter hospitalization with treatment.
|
risk of death, 69.4% lower, RR 0.31, p = 0.34, treatment 1 of 24 (4.2%), control 3 of 22 (13.6%), NNT 11.
|
|
risk of mechanical ventilation, 77.1% lower, RR 0.23, p = 0.18, treatment 1 of 24 (4.2%), control 4 of 22 (18.2%), NNT 7.1.
|
|
risk of ICU admission, 77.1% lower, RR 0.23, p = 0.18, treatment 1 of 24 (4.2%), control 4 of 22 (18.2%), NNT 7.1.
|
|
hospitalization time, 15.4% lower, relative time 0.85, p = 0.01, treatment 24, control 22.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Avdeev et al., 7/9/2021, retrospective, Russia, Europe, peer-reviewed, 4 authors, study period 12 April, 2020 - 20 June, 2020, average treatment delay 7.2 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.